Moderna is standing by its COVID-19 vaccine in the wake of concerns being raised around the world about the jab causing rare heart inflammation in young people.
Seven European nations have either restricted the use of the shot in adults under age 30 or have made a recommendation against its use, in recent weeks.
Data from Swedish public health officials found that young adults – particularly males – who received the shot were more likely to develop myocarditis than those that receive the Pfizer-BioNTech vaccine, spurring the decisions.